IL2 and melanoma: Therefore, we treated mice bearing established, immune-infiltrated (Supplementary Fig. 6), subcutaneous flank B16F10 melanoma tumors with an antibody directed against a tumor-associated antigen tyrosinase-related protein-1 (anti-TYRP-1, or TA99) intraperitoneally and with intratumoral injections of our IL-2 fusion proteins (Fig. 1g).